Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 26, 2021

Primary Completion Date

November 9, 2022

Study Completion Date

November 9, 2022

Conditions

Healthy Subjects

Interventions

DRUG

JYP0061

JYP0061 orally administered

DRUG

placebo

Placebo orally administered

Trial Locations (1)

Shanghai Xuhui District Central Hospital, Shanghai

All Listed Sponsors

lead

Guangzhou JOYO Pharma Co., Ltd

INDUSTRY

NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. | Biotech Hunter | Biotech Hunter